10 results about "Cartilage Matrix" patented technology

This invention provides a stress-triggered selective targeting hydrogel microsphere, its preparation method, and its application, belonging to the field of biomedical technology. The core of this invention is the "stress-triggered charge reversal" mechanism. It utilizes the interaction between weakly cross-linked disulfide bonds broken under stress and "charge reversal" messenger molecules to achieve "charge reversal" of nanoparticles under stress. A dual-network hydrogel microsphere system is prepared using microfluidic technology to achieve bearing lubrication and stress relaxation within the joint cavity. Stress-triggered charge reversal is achieved at stress-overloaded cartilage lesions, imparting a positive charge to the drug-loaded nanoparticles within the hydrogel microspheres. This significantly enhances the ability of the drug-loaded nanoparticles to penetrate deep into the cartilage matrix and target chondrocytes for drug release under the guidance of the charge. This enables the selective and targeted release of appropriate drug concentrations to deep-seated chondrocytes in pathological microenvironments induced by different stress intensities, achieving highly effective and low-toxicity treatment of osteoarthritis.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

This specification discloses an oligonucleotide capable of specifically hybridizing with miR-204, and compositions comprising the oligonucleotide for improving, preventing, or treating osteoarthritis. In one aspect, the oligonucleotide is designed with an optimized structure for miR-204 degradation and formulation stability, effectively blocking pathophysiological processes of osteoarthritis such as decreased cartilage matrix synthesis and increased inflammatory response, thereby preventing or treating osteoarthritis. Furthermore, it exhibits excellent delivery capability to chondrocytes and stable residence within tissues, thus possessing structural advantages for achieving long-term, sustained therapeutic effects. It also has low immunogenicity and toxicity, possessing safety suitable for use in pharmaceutical compositions. In addition, it effectively inhibits miR-204 in canine chondrocytes, therefore it can be used in animal therapeutics and / or feed compositions, etc.

The present application belongs to the technical field of microbial fermentation, and particularly relates to Lactobacillus rhamnosus for maintaining bone health and improving local inflammation of joints, postbiotic and application thereof. The present application prepares a postbiotic product by fermenting and culturing probiotic NKU ML1-2. The results of examples prove that the postbiotic drug can enhance the antioxidant capacity of chondrocytes and osteoblasts, promote the synthesis of anti-inflammatory factors and cartilage matrix (type II collagen and proteoglycan), has the potential to reduce local oxidative stress and inflammatory response of joints, relieve joint inflammation, and delay cartilage destruction. The postbiotic drug prepared by the present application has high safety and good stability, and can be applied to the preparation of drugs for preventing and / or treating osteoarthritis; the postbiotic drug can also be used to promote bone health, enhance the antioxidant capacity of osteoblasts and / or chondrocytes, promote osteoblast activity and / or promote calcium absorption and fixation, and provides a new solution for joint health management.

The present specification provides an oligonucleotide specifically hybridized with miR-204, and a composition for alleviating, preventing or treating osteoarthritis, comprising same. The oligonucleotide according to one aspect of the present invention is designed to have a structure in which miR-204 degradation efficacy and formulation stability are optimized, and effectively blocks pathophysiological processes of osteoarthritis such as decreased cartilage matrix synthesis and increased inflammatory response, and thus is useful for preventing or treating osteoarthritis, and exhibits excellent delivery ability to chondrocytes and stable retention characteristics in tissues, thereby providing a structural advantage of implementing a long-lasting therapeutic effect and safety suitable for use as a pharmaceutical composition since the immunogenicity-inducing potential and toxicity are low, and enabling miR-204 in canine-derived chondrocytes to be effectively inhibited such that the oligonucleotide can be used as an animal therapeutic agent and / or a feed composition.

The present invention relates to a composition for disease-modifying treatment of osteoarthritis. More specifically, the present invention relates to a composition for treating osteoarthritis and a method for treating osteoarthritis by using same, the composition comprising human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and an acellular cartilage matrix.

This invention relates to the field of biomedical materials technology, specifically to a decellularized matrix microparticle-based ink for extrusion 3D printing and its preparation method. The key technical points are: dispersing decellularized matrix microparticles (dECM-MPs) in a metal ion solution for ion adsorption; the dECM-MPs include cartilage matrix microparticles (DCM-MPs) or bone matrix microparticles (DBM-MPs); then, without damaging the structure and composition of the dECM-MPs, forming a hydrogel microlayer in situ on the surface of the dECM-MPs through interfacial ion diffusion crosslinking; centrifuging the dECM-MPs encapsulated in the hydrogel microlayer to obtain an ink suitable for extrusion 3D printing; and using this 3D printing ink to print and then fixing it with ultraviolet light to obtain a 3D printed implant. The particulate ink prepared by this invention has good printability, overcoming the significant challenge of 3D printing hard tissue microparticles.

This invention belongs to the field of nutritional composition technology, specifically relating to a composition, composition formulation, preparation method, application, and product for improving bone health. This invention provides a composition composed of N-acetylglucosamine and 3-O-acetyl-11-keto-β-boswellic acid. The composition and formulation of this invention can promote the differentiation of chondrocyte precursor cells into mature chondrocytes, promote cartilage matrix synthesis, significantly inhibit TNF-α and MMP13 expression, and upregulate COL2A1 expression, with effects superior to single components and traditional combinations. The ingredients are natural and safe, biocompatible, and have no significant toxicity, making them suitable for people with joint noise, joint pain, osteoarthritis, and joint degeneration. Simultaneously, they can improve bone density, promote bone growth and development, and improve bone health. The preparation process is simple and low-cost, and it can be formulated into various dosage forms such as food, health products, and pharmaceuticals, offering flexible applications and combining preventative and therapeutic value.

The application relates to the technical field of biological medicine, in particular to an engineered mesenchymal stem cell sphere exosome and a preparation method and application thereof. The method comprises the following steps: O-GlcNAc glycosylation modification is performed on mesenchymal stem cells to obtain O-GlcNAc glycosylation modified mesenchymal stem cells; the mesenchymal stem cells are subjected to sphere formation culture to form mesenchymal stem cell spheres; and three-dimensional culture is performed to make the mesenchymal stem cell spheres secrete exosomes containing hsa-miR-423-3p. The exosomes can efficiently deliver hsa-miR-423-3p to target cells, activate a mitochondrial autophagy pathway, selectively remove damaged mitochondria, thereby block ROS excessive release, maintain the level of GSH, SOD and other antioxidant substances, reduce oxidative stress damage, and finally promote chondrocyte survival and cartilage matrix synthesis.

This invention relates to a method for quantitatively detecting residual DNA and glycosaminoglycan (GAG) levels in cartilage tissue-engineered samples. The method involves enzymatically digesting decellularized cartilage matrix samples using a combination enzyme, wherein the combination enzyme consists of papain and bromelain, with a mass ratio of papain to bromelain of 1-3:1. The digested sample is then centrifuged and ultrafiltered to obtain a test liquid containing DNA and GAG. DNA and GAG detection are then performed on the test liquid containing DNA and GAG, respectively. This invention, through the selection of enzyme types, allows the digested sample to be used for both DNA and GAG detection, improving detection efficiency and reducing the amount of tissue-engineered sample required, thus lowering sample usage costs.